Beijing Yuanhefa Biotechnology

Beijing Yuanhefa Biotechnology is a Chinese biotechnology company specializing in the development of stem cell-based therapies for regenerative medicine. Founded in the early 2000s, the company was a pioneer in the Chinese cell therapy sector, focusing on the application of mesenchymal stem cells (MSCs) for cardiovascular repair. Its lead program, an autologous mesenchymal stem cell injection for myocardial infarction, was one of the first stem cell products to receive clinical trial approval from the SFDA (now NMPA) in 2005. The company successfully completed a Phase I clinical trial for this indication in 2012, demonstrating the safety and feasibility of its approach. While the company was an early leader in the field, its recent clinical development progress has been less publicized following regulatory changes in the Chinese stem cell industry.